Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
More News: Clinical Trials | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Obesity | Pfizer | Pharmaceuticals | Statistics | Study